What is William Blair’s Estimate for IONS Q1 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Ionis Pharmaceuticals in a research report issued on Wednesday, February 19th. William Blair analyst M. Minter forecasts that the company will earn ($1.17) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. William Blair also issued estimates for Ionis Pharmaceuticals’ Q2 2026 earnings at ($1.07) EPS, Q3 2026 earnings at ($0.89) EPS and Q4 2026 earnings at ($0.85) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.46. The firm had revenue of $227.00 million for the quarter, compared to the consensus estimate of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company’s revenue was down 30.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.12 EPS.

IONS has been the subject of several other research reports. Wells Fargo & Company dropped their price target on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. BMO Capital Markets reduced their price objective on Ionis Pharmaceuticals from $60.00 to $45.00 and set a “market perform” rating for the company in a research note on Thursday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $70.00 target price on shares of Ionis Pharmaceuticals in a research report on Thursday. StockNews.com cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a report on Thursday. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Ionis Pharmaceuticals Trading Down 1.1 %

Shares of Ionis Pharmaceuticals stock opened at $32.33 on Monday. The firm has a market capitalization of $5.14 billion, a PE ratio of -10.63 and a beta of 0.34. The company has a current ratio of 8.47, a quick ratio of 8.82 and a debt-to-equity ratio of 2.12. The firm’s 50 day moving average is $33.65 and its 200 day moving average is $38.24. Ionis Pharmaceuticals has a 1 year low of $30.23 and a 1 year high of $52.34.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its position in shares of Ionis Pharmaceuticals by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock worth $106,922,000 after buying an additional 183,814 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Ionis Pharmaceuticals by 967.2% in the 4th quarter. Assenagon Asset Management S.A. now owns 141,917 shares of the company’s stock worth $4,961,000 after purchasing an additional 128,619 shares during the period. SG Americas Securities LLC lifted its stake in shares of Ionis Pharmaceuticals by 222.5% during the 4th quarter. SG Americas Securities LLC now owns 23,927 shares of the company’s stock worth $836,000 after purchasing an additional 16,508 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Ionis Pharmaceuticals by 8.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company’s stock valued at $57,807,000 after buying an additional 114,914 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Ionis Pharmaceuticals by 13.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 650,779 shares of the company’s stock valued at $26,070,000 after buying an additional 77,909 shares during the last quarter. 93.86% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Patrick R. O’neil sold 6,165 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $31.62, for a total transaction of $194,937.30. Following the transaction, the executive vice president now owns 57,452 shares in the company, valued at approximately $1,816,632.24. This represents a 9.69 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Brett P. Monia sold 33,445 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $32.63, for a total transaction of $1,091,310.35. Following the transaction, the chief executive officer now owns 207,396 shares in the company, valued at approximately $6,767,331.48. This trade represents a 13.89 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 110,609 shares of company stock valued at $3,564,867. 2.71% of the stock is currently owned by company insiders.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.